Trial · NCT07879560
Ramipril vs. Amlodipine in Pediatric Hemodialysis Patients
NCT07879560, Phase 3, Not yet recruiting, Ain Shams University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ramipril vs. Amlodipine in Pediatric Hemodialysis Patients. Trials, record NCT07879560. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07879560
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ramipril vs. Amlodipine in Pediatric Hemodialysis Patients
- NCT number
- NCT07879560
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Ain Shams University
- Conditions
- Endothelial Dysfunction, End-Stage Renal Disease, Pediatric Kidney Disease
- Interventions
- Ramipril tablet, Amlodipine tablet
- First posted
- 2026-10-19
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum asymmetric dimethylarginine (ADMA) level as a marker of endothelial dysfunction | 1.Baseline: before initiation of antihypertensive treatment (Ramipril or Amlodipine) 2.End of treatment: at 3 months after completing the assigned treatment. | Endothelial dysfunction marker: Serum asymmetric dimethylarginine (ADMA) level Blood samples will be collected from each patient at two predefined time points throughout the study: 1. Baseline: before initiation of antihypertensive treatment (Ramipril or Amlodipine) 2. End of treatment: at 3 months after completing the assigned treatment. Blood samples will be drawn prior to the hemodialysis session, centrifuged, and stored at -80 °C until analysis. Serum levels of ADMA will be measured using enzyme-linked immunosorbent assay (ELISA) techniques. |
| Secondary | Serum Fetuin-A level as a marker of vascular calcification. | 1.Baseline: before initiation of antihypertensive treatment (Ramipril or Amlodipine) 2.End of treatment: at 3 months after completing the assigned treatment. | Serum Fetuin-A will be assessed at baseline and at the end of treatment (3 months) using ELISA kits, following the same sampling and storage procedures as ADMA. |
| Secondary | Blood pressure control | throughout the 3-month treatment period | Systolic and diastolic blood pressure will be measured before dialysis sessions. Blood pressure readings will be recorded at baseline and throughout the 3-month treatment period, and mean values will be used for analysis to evaluate the antihypertensive efficacy of Ramipril and Amlodipine. |
| Secondary | Quality of life (QOL)using the Pediatric Quality of Life Inventory (PedsQL) 3.0 End Stage Renal Disease (ESRD) Module | At baseline At the end of treatment period (after 3 months) | Quality of life will be assessed using the validated Arabic version of the Pediatric Quality of Life Inventory™ 3.0 End-Stage Renal Disease Module (PedsQL™ 3.0 ESRD), which is specifically designed for use in children and adolescents with end-stage renal disease undergoing dialysis. The questionnaire will be administered: At baseline At the end of treatment period (after 3 months) Quality of life will be assessed using the Pediatric Quality of Life Inventory (PedsQL) 3.0 End Stage Renal Disease (ESRD) Module. Items are rated on a 5-point scale ranging from 0 to 4 (0 = Never / no problem, 1 = Almost never, 2 = Sometimes, 3 = Often, 4 = Almost always / greatest problems). Items are reverse-scored and transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0). Total and domain scores are calculated as the mean of the transformed items, with final scores ranging from a minimum of 0 to a maximum of 100. Higher scores indicate better health-related quality of life. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07879560
GET https://conductscience.org/api/trials/v1/NCT07879560/registered